(IRB# 20-001502) Ronald Reagan UCLA Medical Center, Drug Information Center

Los Angeles, California 90095

0 studies enrolling now · 1 studies all time

What they study most

HER2 Positive Breast Cancer

Studies at this site

• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed